Page 2512 - Williams Hematology ( PDFDrive )

2483
2482 Index Index 2483

marrow, 1322t, 1325t, 1326–1327 Progesterone, 901 characteristics, 1952t
monocytosis, 1096 Programmed cell death, 203. See also in coagulation reactions, 1949, 2201
plasma and urine chemical, 1322t, 1325, Apoptosis in platelets, 1843
1327 Programmed death-1 (PD-1), 424, 1755 signaling, 1956, 1957f, 2076
therapy, 1328–1331 Programmed death-1 (PD-1) receptor, 416 Protease (proteinase)-activated receptors
androgens and glucocorticoids for Progressive multifocal leukoencephalopathy (PARs), 290
anemia, 1328 (PML), 1536 Protease–cofactor complexes, 1917–1918,
bisphosphonates for bone disease, 1330 Prolactin, 561 1918t
decision to treat, 1328 Proline hydroxylase deficiency, 878 Protease inhibitors, 1242, 1249, 1941–1942,
drug therapy for myeloproliferation, Proline hydroxylases (PHDs), 486, 486f 1958–1959. See also Antithrombin
splenomegaly or cytopenias, Prolymphocytic (prolymphoblastic) leukemia (AT); Heparin
1328–1330, 1329t (PLL) Proteasome, 240–241
hematopoietic cell transplantation, chromosomal abnormalities, 187, 223t, Proteasome inhibitors, 209, 342–343, 342f,
1330–1331 225, 1494t 1750–1751, 1754. See also specific
intravenous immunoglobulin, 1330 chronic lymphocytic leukemia and, drugs
portal-systemic vascular shunt surgery, 1542 Protectins, 286
1330 gene mutations, 1494t Protein 4.1R, 663t, 666–667, 667f, 670t,
radiotherapy, 1330 laboratory features, 1494t 678
recombinant human erythropoietin for ProMACE/CytaBOM regimen Protein 4.2, 663t, 667, 670t, 672
anemia, 1328 for diffuse large B-cell lymphoma, Protein antigens, 2337
red cell transfusion, 1328 1629–1630 Proteinase 3, 283, 414, 1012t, 1013
ruxolitinib, 341–342 for posttransplant lymphoproliferative Proteinase (protease)-activated receptors
splenectomy, 1330 disorders, 1636 (PARs), 290. See also Protease
for thrombosis and bleeding, 2081 ProMACE/MOPP regimen, for follicular (proteinase)-activated receptor
transitions to and from, 1328 lymphoma, 1644 (PAR)-1
Primary pituitary lymphoma, 1579 Promegaloblasts, 595f Protein C, 1951–1952
Primary polycythemia. See Polycythemia Promonocytes, 34, 1046 activation, 1923. See also Activated protein
(erythrocytosis), primary familial Promyelocytes C (APC)
and congenital marrow, 32t, 34 antibodies, 2187
Primary testicular lymphoma, 1246, maturation, 926f, 940–941, 940f, 941t endothelial protein C receptor and, 1953
1581–1582, 1582f, 1634 structure, 925, 927f functions, 1952t
Primary thrombocythemia, vs. primary Promyelocytic leukemia, 1390 gene structure and variations, 1923, 1923f,
myelofibrosis, 1327 Proplatelets, 72, 73f, 1815, 1818, 1820f 1952
Primary thyroid lymphoma, 1583 Propofol, 28 mutations, 1952
Primidone, megaloblastic anemia and, 606t Propranolol, 2078 structure, 1854, 1917f, 1923, 1951–1952,
Prion protein, 1871 PROS1, 1926–1927, 1928f 1951f, 1952t
Prions, 2126 Prostacyclin (prostaglandin I ) synthesis, 1951–1952
2
PRKAR1B, 1853 antiplatelet effects, 404, 1885, 1967, 2074 therapeutic forms, 1952
Proband, 148 as autacoid, 1970 thrombomodulin and, 1953, 1972
Pro-B cell, 270 in HELLP syndrome, 801 Protein C deficiency
PROC, 1923, 1923f inflammation and, 288–289, 2202 acquired causes, 2224t
Procainamide, 2015 synthesis, 1834, 1969–1970 clinical features, 2100, 2223
Procarbazine. See also BEACOPP regimen; Prostacyclin G/H synthase, 1970 clinical implications of testing for, 2228t
COPP regimen; MOPP regimen Prostaglandin E , 1182, 1885 epidemiology, 2222t
2
for α-heavy-chain disease, 1808 Prostaglandin H synthase-1 etiology and pathogenesis, 1923, 1952,
2
mechanism of action, 329 (cyclooxygenase) deficiency, 2058 2222–2223
pharmacology, 330 Prostaglandin I . See Prostacyclin venous thromboembolism risk and, 2225t,
2
resistance to, 319t Prostaglandins, 404, 1885, 2074. See also 2226t
Procoagulants, 1285 Eicosanoids Protein C pathway
PROCR, 1932 Prostate, primary lymphomas in, 1572 antiphospholipid antibodies and, 2237
Proerythroblasts, 32t, 34, 463–464, 463f, 464f, Prosthetic heart valves, hemolysis and, coagulation pathways and, 1949–1951,
482t 804–806, 805t 1950f
Profilin, 1832t, 1841 Protamine, for heparin reversal, 397 components, 1951–1954, 1952t
Progenitor cell leukemia, 1283 Protease (proteinase)-activated receptor endothelial protein C receptor. See
Progenitor cells. See Hematopoietic (PAR)-1, 290, 1954 Endothelial protein C receptor
progenitors activation, 1877, 1877f, 1881 (EPCR)

Kaushansky_index_p2393-2506.indd 2483 9/21/15 3:22 PM